$ANIP

ANI Pharmaceuticals (ANIP) appointed Henry Gosebruch to its board, replacing Muthusamy Shanmugam, who will remain in operational roles. Gosebruch has biotech leadership experience. The company, with a $1.6b market cap, develops and markets branded and generic drugs. Board changes may influence capital allocation and product mix.

ANI Pharmaceuticals Inc. (ANIP) filed an Initial Statement of Beneficial Ownership (Form 3) on August 19, 2026, disclosing a director's ownership of securities. The company is a diversified biopharmaceutical firm focused on rare disease treatments and generic pharmaceuticals, with segments including Rare Disease, Brands, and Generics.

ANI PHARMACEUTICALS INC (ANIP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors – Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., August 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Compa

ANI Pharmaceuticals (ANIP) reported Q2 and first-half 2026 results, reaffirming its net revenue outlook. The stock is down 0.90% in one day and 6.53% over 90 days, but up 176.54% over 5 years. The company is trading at $77.32, below a fair value estimate of $112.71, with growth potential in Cortrophin Gel and other rare disease products.

ANI Pharmaceuticals (ANIP) reported Q2 2026 earnings with total revenue of $266.0 million, up 25.9% YoY, driven by Rare Disease and Generics segments. Adjusted EBITDA rose 32.4% to $71.6 million, exceeding expectations. Cortrophin Gel revenue increased 43.5% to $117.1 million. The company reaffirmed full-year revenue guidance of $1.08B-$1.14B but lowered Cortrophin Gel outlook to $520M-$540M. Management highlighted progress in rare disease focus and sales force expansion.

A peer comparison of Q2 results in generic pharmaceuticals says the four tracked companies beat analysts’ revenue consensus by 2.6% on average, but shares fell 5.6% since reporting. ANI Pharmaceuticals (ANIP) revenue was $266m (+25.9%), EPS beat, but full-year revenue guidance missed; stock down 9.1% to $75.12. Amphastar (AMPH) revenue $183.9m (+5.4%) beat; stock up 2.3% to $20.28. Viatris (VTRS) revenue $3.76b (+4.9%) beat; stock down 7.6% to $16.32. Amneal (AMRX) revenue $796.2m (+9.9%) beat;

ANI Pharmaceuticals reported Q2 2026 sales of $266.04 million and net income of $24.71 million, and reaffirmed full-year 2026 net revenue guidance of $1.08 billion to $1.14 billion, according to the company. The article links results to rare disease therapy Cortrophin Gel and the generics portfolio.

ANI Pharmaceuticals (ANIP) trades at 7.6x forward 12-month EPS versus higher peers and market benchmarks. Zacks consensus projects 2026 revenue of $1.10B (+24.6%) and EPS of $9.40 (+19.1%). Cortrophin guidance was cut to $520-$540M, making it about 48% of revenue at midpoints, raising execution risk.

ANI Pharmaceuticals reported Q2 adjusted EPS of $2.21 and revenue of $266M, both above consensus. Cortrophin Gel revenue rose 43.5% to $117.1M but missed $120.4M. For 2026, ANI cut Cortrophin guidance to $520-$540M from $540-$575M while keeping total revenue $1.08-$1.14B and EPS $9.19-$9.69.

ANI Pharmaceuticals reported Q2 2026 total net revenues of $266.0 million, up 25.9% year over year, and adjusted non-GAAP EBITDA of $71.6 million, up 32.4%. Cortrophin Gel revenues were $117.1 million (+43.5%). 2026 guidance: net revenue $1.08B-$1.14B, Cortrophin Gel $520M-$540M, adjusted EBITDA $285M-$300M, EPS $9.19-$9.69.